1,016 results on '"Cohen, Alexander T."'
Search Results
52. Derivation and validation of a composite scoring system (SAVED2) for prediction of unfavorable modified Rankin scale score following intracerebral hemorrhage
53. Abstract WP126: Predictors Of Intracranial Hemorrhage Volume Expansion In Patients Receiving Factor Xa Inhibitors In The Annexa-4 Trial
54. A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK
55. Limitations of venous thromboembolism risk assessment models in medical patients: Response to “Unmet definitions in thromboprophylaxis for hospitalized medical patients: An appraisal for the need of recommendation”
56. Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program
57. Thromboembolic Prevention in Frail Elderly Patients With Atrial Fibrillation: A Practical Algorithm
58. External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial
59. Redefining clinical venous thromboembolism phenotypes: a novel approach using latent class analysis
60. Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial
61. N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy
62. Effectiveness and Safety of Anticoagulants in Cancer Patients with VTE and Kidney Disease
63. Rivaroxaban Versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism: A Head-to-Head Analysis of the United States Cohort of the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban: (H2H-OSCAR-US)
64. Comparison of Rivaroxaban and Low Molecular Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism
65. Early Time Courses of Recurrent Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer
66. Cost‐of‐Illness Analysis of Long‐Term Health Care Resource Use and Disease Burden in Patients With Pulmonary Embolism: Insights From the PREFER in VTE Registry
67. Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
68. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials
69. Managing pulmonary embolism from presentation to extended treatment
70. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial)
71. COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study
72. Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study
73. Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study
74. Occurrence and predictors of recurrence after a first episode of acute venous thromboembolism: population-based Worcester Venous Thromboembolism Study
75. Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evaluated in a randomized controlled trial in England
76. Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy
77. Cost-of-Illness Analysis of Long-Term Health Care Resource Use and Disease Burden in Patients With Pulmonary Embolism: Insights From the PREFER in VTE Registry
78. Abstract 20444: Betrixaban Reduces Not Only the Presence of Thrombus but Also Extent of Thrombus: An APEX Trial Substudy
79. Abstract 20393: Full-Dose Betrixaban Reduces Venous Thromboembolism-Related Mortality: An APEX Trial Substudy
80. Abstract 20322: Extended-Duration Betrixaban Reduces the Risk of Venous Thromboembolism-Related Rehospitalization Among Acutely Ill Hospitalized Medical Patients: An APEX Trial Substudy
81. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
82. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial
83. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)
84. The Novel Oral Anticoagulants for Acute Venous Thromboembolism: Is Warfarin Dead?: Controversies and Evolving Concepts in Deep Venous Thrombosis and Pulmonary Embolism
85. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score.
86. How I manage venous thromboembolism risk in hospitalized medical patients
87. PL-30 Thromboprophylaxis in non-surgical cancer patients
88. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials
89. Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study
90. Identification of undiagnosed atrial fibrillation using a machine learning risk-prediction algorithm and diagnostic testing (PULsE-AI) in primary care: a multi-centre randomized controlled trial in England
91. Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding
92. Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial
93. Prevention of postoperative venous thromboembolism
94. Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
95. Prevention of VTE in women with cancer
96. Abstract WMP83: Derivation And Validation Of The SAVED 2 Score For Prediction Of Unfavorable Modified Rankin Scale Score Following Intracerebral Hemorrhage
97. Splanchnic vein thrombosis-related mortality in the Veneto region (Italy), 2008–2019: Retrospective analysis of epidemiological data
98. Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective
99. Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
100. Efficacy And Safety Of Fondaparinux For The Prevention Of Venous Thromboembolism In Older Acute Medical Patients: Randomised Placebo Controlled Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.